Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment

Nirmatrelvir coadministered with ritonavir is highly efficacious in reducing the risk of coronavirus disease 2019 (COVID‐19) adverse outcomes among patients at increased risk of progression to severe disease, including patients with chronic kidney disease. Because nirmatrelvir is eliminated by the k...

Descripción completa

Detalles Bibliográficos
Autores principales: Toussi, Sima S., Neutel, Joel Michael, Navarro, Jesus, Preston, Richard Alfred, Shi, Haihong, Kavetska, Olga, LaBadie, Robert R., Binks, Michael, Chan, Phylinda L.S., Demers, Neil, Corrigan, Brian, Damle, Bharat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349773/
https://www.ncbi.nlm.nih.gov/pubmed/35712797
http://dx.doi.org/10.1002/cpt.2688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349773/
https://www.ncbi.nlm.nih.gov/pubmed/35712797
http://dx.doi.org/10.1002/cpt.2688

Ejemplares similares